Organon & Co Ordinary Shares OGN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference
-
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
-
Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability
-
Organon Announces Quarterly Dividend
-
New Analysis of Phase 3 Pooled Data for Organon’s VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1
-
Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
-
Organon to Present New Analysis on VTAMA® (tapinarof) cream, 1%, at the 2026 Society for Pediatric Dermatology Annual Meeting
-
India's Sun Pharma to Buy U.S. Healthcare Company Organon in $11.75 Billion Deal — 2nd Update
Trading Information
- Previous Close Price
- $13.71
- Day Range
- $13.71–13.75
- 52-Week Range
- $5.69–13.79
- Bid/Ask
- $13.72 / $13.74
- Shares Outstanding
- 262.61M
- Market Cap
- $3.60B
- Volume/Avg
- 2M / 3M
Key Statistics
- Price/Earnings (Normalized)
- 4.28
- Price/Sales
- 0.59
- Dividend Yield (Trailing)
- 0.58%
- Dividend Yield (Forward)
- 0.58%
- Dividend Payment Schedule
- Mar, Jun, Sep, Dec
- Total Yield
- 0.58%
Company Profile
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Small Value
- Total Number of Employees
- 10,000
- Website
- https://www.organon.com
Valuation
|
Metric
|
OGN
|
|---|---|
Price/Earnings (Normalized) | 4.28 |
Price/Book Value | 3.58 |
Price/Sales | 0.59 |
Price/Cash Flow | 4.11 |
Price/Earnings
OGN
Financial Strength
|
Metric
|
OGN
|
|---|---|
Quick Ratio | 1.00 |
Current Ratio | 1.95 |
Interest Coverage | 2.05 |
Quick Ratio
OGN
Profitability
|
Metric
|
OGN
|
|---|---|
Return on Assets (Normalized) | 4.19% |
Return on Equity (Normalized) | 64.45% |
Return on Invested Capital (Normalized) | 9.67% |
Return on Assets
OGN
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|BQ&M>rwd | LOCK|gj | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|h$Skp>Y | LOCK|S! | $623B | |||
| AbbVie Inc
ABBV
| LOCK|t>V?$J | LOCK|HY | $459B | |||
| Merck & Co Inc
MRK
| LOCK|^>MV!hz | LOCK|G! | $355B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|PQG@GMt | LOCK|!N | $334B | |||
| Novartis AG ADR
NVS
| LOCK|t>v<K@Y | LOCK|Q$ | $268B | |||
| AstraZeneca PLC
AZN
| LOCK|%f&%Z&> | LOCK|!wj | $248B | |||
| Amgen Inc
AMGN
| LOCK|RMt@$ycj | LOCK|&B | $220B | |||
| Gilead Sciences Inc
GILD
| LOCK|?^<bT! | LOCK|>p | $183B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|nM^<sf% | LOCK|^x^ | $167B |
United States